Engineered neutrophil engagers overcome IgA limitations and reprogram resting neutrophils for cancer immunotherapy
These findings define IgG-based CD89 bispecifics as a next-generation neutrophil engager platform and exemplify how antibody engineering and synthetic immunology can be leveraged to expand the effector landscape of bispecific immunotherapies.
Authors
- Munsu Kyung
- Sang Taek Jung (ORCID: https://orcid.org/0000-0001-7217-979X)
- G. Celine Han (ORCID: https://orcid.org/0000-0003-2004-8186)
- Seunghyeon Lee (ORCID: https://orcid.org/0000-0003-2356-3677)
- Tae Woo Kim (ORCID: https://orcid.org/0000-0001-6183-6010)
- Jisun Lee (ORCID: https://orcid.org/0000-0003-1750-0063)
Institutions
- Seoul National University (KR)
- Korea University (KR)
- National University (SD)
- National University College (PR)
- Korea University (JP)
Publication Details
- Journal
- Journal of Biological Engineering
- Published
- 2025-12-05
- DOI
- https://doi.org/10.1186/s13036-025-00580-2
- Citations
- 1
- Primary Topic
- Monoclonal and Polyclonal Antibodies Research
- Type
- article
- Field-Weighted Citation Impact
- 1.36
Funders
- National Research Foundation
- National Research Foundation of Korea
- Korea Drug Development Fund
- Ministry of Education, India
- Ministry of Science and ICT, South Korea